205 related articles for article (PubMed ID: 30394686)
1. Intratumoral temozolomide in spontaneous canine gliomas: feasibility of a novel therapy using implanted microcylinders.
Hicks J; Platt S; Stewart G; Senneca C; Holmes S; Kent M; Howerth E; Kaplan J; Kaplan E
Vet Med Sci; 2019 Feb; 5(1):5-18. PubMed ID: 30394686
[TBL] [Abstract][Full Text] [Related]
2. Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas.
Dolera M; Malfassi L; Bianchi C; Carrara N; Finesso S; Marcarini S; Mazza G; Pavesi S; Sala M; Urso G
Vet Comp Oncol; 2018 Mar; 16(1):90-101. PubMed ID: 28643878
[TBL] [Abstract][Full Text] [Related]
3. Safety and feasibility of the NanoKnife system for irreversible electroporation ablative treatment of canine spontaneous intracranial gliomas.
Rossmeisl JH; Garcia PA; Pancotto TE; Robertson JL; Henao-Guerrero N; Neal RE; Ellis TL; Davalos RV
J Neurosurg; 2015 Oct; 123(4):1008-25. PubMed ID: 26140483
[TBL] [Abstract][Full Text] [Related]
4. Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017).
Moirano SJ; Dewey CW; Wright KZ; Cohen PW
Vet Comp Oncol; 2018 Dec; 16(4):459-466. PubMed ID: 29797768
[TBL] [Abstract][Full Text] [Related]
5. Convection-enhanced delivery of cetuximab conjugated iron-oxide nanoparticles for treatment of spontaneous canine intracranial gliomas.
Freeman AC; Platt SR; Holmes S; Kent M; Robinson K; Howerth E; Eagleson J; Bouras A; Kaluzova M; Hadjipanayis CG
J Neurooncol; 2018 May; 137(3):653-663. PubMed ID: 29350351
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
Rudà R; Pellerino A; Pace A; Carapella CM; Dealis C; Caroli M; Faedi M; Bello L; Migliore E; Marchese G; Bertero L; Cassoni P; Soffietti R
J Neurooncol; 2019 Oct; 145(1):115-123. PubMed ID: 31556015
[TBL] [Abstract][Full Text] [Related]
8. The NRG3/ERBB4 signaling cascade as a novel therapeutic target for canine glioma.
Noguchi S; Inoue M; Ichikawa T; Kurozumi K; Matsumoto Y; Nakamoto Y; Akiyoshi H; Kamishina H
Exp Cell Res; 2021 Mar; 400(2):112504. PubMed ID: 33508276
[TBL] [Abstract][Full Text] [Related]
9. [Glioma therapy up-date].
de la Fuente BP; Dalmau J; Rosenfeld M
Neurologia; 2007 Apr; 22(3):159-69. PubMed ID: 17364254
[TBL] [Abstract][Full Text] [Related]
10. Naturally Occurring Canine Glioma as a Model for Novel Therapeutics.
Hubbard ME; Arnold S; Bin Zahid A; McPheeters M; Gerard O'Sullivan M; Tabaran AF; Hunt MA; Pluhar GE
Cancer Invest; 2018; 36(8):415-423. PubMed ID: 30234401
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide chemotherapy in patients with recurrent malignant gliomas.
Yang SH; Kim MK; Lee TK; Lee KS; Jeun SS; Park CK; Kang JK; Kim MC; Hong YK
J Korean Med Sci; 2006 Aug; 21(4):739-44. PubMed ID: 16891823
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide and treatment of malignant glioma.
Friedman HS; Kerby T; Calvert H
Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
[TBL] [Abstract][Full Text] [Related]
14. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Izquierdo C; Alentorn A; Idbaih A; Simó M; Kaloshi G; Ricard D; Barritault M; Meyronet D; Bruna J; Honnorat J; Delattre JY; Ducray F
J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
[TBL] [Abstract][Full Text] [Related]
15. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Sipos L; Vitanovics D; Afra D
Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
[TBL] [Abstract][Full Text] [Related]
17. COX-2 and c-kit expression in canine gliomas.
Jankovsky JM; Newkirk KM; Ilha MR; Newman SJ
Vet Comp Oncol; 2013 Mar; 11(1):63-9. PubMed ID: 22235799
[TBL] [Abstract][Full Text] [Related]
18. The use of temozolomide in recurrent malignant gliomas.
Gaya A; Rees J; Greenstein A; Stebbing J
Cancer Treat Rev; 2002 Apr; 28(2):115-20. PubMed ID: 12297119
[TBL] [Abstract][Full Text] [Related]
19. An open-label dose escalation study evaluating tolerability and safety of a single 5-days course of temozolomide in dogs with advanced cancer.
Marconato L; Rohrer Bley C; Leone VF; Finotello R
Vet Comp Oncol; 2020 Dec; 18(4):838-842. PubMed ID: 32510792
[TBL] [Abstract][Full Text] [Related]
20. Convection-Enhanced Delivery of Polymeric Nanoparticles Encapsulating Chemotherapy in Canines with Spontaneous Supratentorial Tumors.
Young JS; Bernal G; Polster SP; Nunez L; Larsen GF; Mansour N; Podell M; Yamini B
World Neurosurg; 2018 Sep; 117():e698-e704. PubMed ID: 29960096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
